SYS-CON MEDIA Authors: RealWire News Distribution, Cynthia Dunlop, Mark O'Neill, Kevin Benedict

News Feed Item

Rx&D applauds introduction of New Brunswick Drug Plan

OTTAWA, ONTARIO -- (Marketwired) -- 12/11/13 -- Canada's Research-Based Pharmaceutical Companies (Rx&D) applauds the government of New Brunswick on the announcement of its new drug plan.

"We support the government's vision and commitment to improving their provincial drug program which will help New Brunswickers avoid catastrophic drug costs", said Russell Williams, President of Rx&D. "This announcement will have a profound impact for New Brunswickers, including some 70,000 families currently without drug coverage."

Today's announcement of the New Brunswick Drug Plan builds upon the December 2012 Report of the Advisory Committee on Health Benefits after consultation with a wide array of stakeholders including residents, patient groups, business, and the pharmaceutical industry. Rx&D was pleased to contribute to this policy development effort and also congratulates the health charities and patient organizations involved for their tremendous efforts in achieving positive policy change.

"We are fully aware of the sustainability challenge which all governments face when it comes to health system policy, design and delivery choices. The appropriate use of innovative medicines and vaccines is an enabler of healthcare sustainability," added Mr. Williams. "Today's announcement of this new program coming into effect in 2014 will offer New Brunswickers better access to the medicines and therapies that they need to manage their health. Initiatives, such as this one, contribute to sustainable healthcare by better managing disease, keeping employees off disability and at work, and promoting productive citizens of all ages."

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development each year to fuel Canada's knowledge-based economy, contributing over $3 billion to the Canadian economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.

Contacts:
Julie Harris
Media Relations, Rx&D
613-236-0455 extension 212
jharris@canadapharma.org

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.